| Scrip Code | 544645 |
|---|---|
| NSE Symbol | PARKHOSPS |
| MSEI Symbol | NOTLISTED |
| ISIN | INE119201023 |
| Name of company | PARK MEDI WORLD LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 03-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 29-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | Healthcare Services |
| Start date and time of board meeting | 03-08-2026 08:00:00 |
| End date and time of board meeting | 03-08-2026 09:20:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 47,570.90 | 47,570.90 | |
| Other income | 764.60 | 764.60 | |
| Total income | 48,335.50 | 48,335.50 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 7,712.40 | 7,712.40 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (86.70) | (86.70) |
| (d) | Employee benefit expense | 9,240.70 | 9,240.70 |
| (e) | Finance costs | 981.00 | 981.00 |
| (f) | Depreciation, depletion and amortisation expense | 1,884.00 | 1,884.00 |
| (f) | Other Expenses | ||
| 1 | Professional and consultancy fees | 7,560.50 | 7,560.50 |
| 2 | Other expenses | 10,535.20 | 10,535.20 |
| Total other expenses | 18,095.70 | 18,095.70 | |
| Total expenses | 37,827.10 | 37,827.10 | |
| 3 | Total profit before exceptional items and tax | 10,508.40 | 10,508.40 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 10,508.40 | 10,508.40 |
| 6 | Tax expense | ||
| 7 | Current tax | 2,583.10 | 2,583.10 |
| 8 | Deferred tax | (934.00) | (934.00) |
| 9 | Total tax expenses | 1,649.10 | 1,649.10 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 8,859.30 | 8,859.30 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 8,859.30 | 8,859.30 |
| 17 | Other comprehensive income net of taxes | (58.10) | (58.10) |
| 18 | Total Comprehensive Income for the period | 8,801.20 | 8,801.20 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 8,250.70 | 8,250.70 | |
| Total profit or loss, attributable to non-controlling interests | 608.60 | 608.60 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | (56.90) | (56.90) | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | (1.20) | (1.20) | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 8,638.60 | 8,638.60 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 2.05 | 2.05 | |
| Diluted earnings (loss) per share from continuing operations | 2.05 | 2.05 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 2.05 | 2.05 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 2.05 | 2.05 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes to the unaudited Consolidated financial results for the quarter ended June 30, 2026: 1. The unaudited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 “Interim Financial Reporting” notified under Section 133 of the Companies Act, 2013 (“the Act”) read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations). 2. The unaudited Consolidated financial results (‘the Statement) of Park Medi World Limited (‘the company’) for the quarter ended June 30, 2026 were reviewed by the Audit committee on August 03, 2026 and approved by the Board of Directors at its meeting held on August 03, 2026 in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the statutory auditors of the company who have issued an unmodified opinion on the same. 3. The Company has launched a 350 bedded advanced multi-super specialty hospital at Panchkula on April 10, 2026. The Panchkula hospital is equipped with advanced diagnostics, modular operation theatres, critical care infrastructure, and will deliver comprehensive care across key specialties including oncology, neurosciences, orthopaedics, cardiology, and critical care including robotic-assisted procedures. 4. The Company has successfully acquired 80% shareholding of V3 Healthcare Private Limited on July 31, 2026 which operates a multi-super speciality Hospital in the name of “The Medicity Hospital - Rudrapur”, Uttaranchal having capacity of 330 beds. Remaining 20% will be acquired by April 30, 2030. Overall cost of acquisition is approx. Rs. 1,770 millions. Consequent to this acquisition, V3 Healthcare Private Limited has become a subsidiary of the Company. Further, the Hospital has been launched on August 2, 2026. 5. RGS Healthcare Limited, the step down subsidiary of the Company, has proposed the expansion of its Mohali unit from 350 beds to 500 beds. The overall cost of expansion will be approx. Rs. 400 millions which is proposed to be funded through internal accruals. Umkal Healthcare Private Limited , the wholly owned subsidiary of the Company, has proposed the expansion of its existing 225-beded Park Hospital in Palam Vihar, Gurugram, with addition of 100 new beds. The newly expanded facility will be branded as Park Hospital Platinum and the proposed capacity addition is to be completed by November 2026. Overall cost of additional beds will be approx. Rs. 250 millions which is proposed to be funded from internal accruals. 6. Park Medicenters and Institutions Private Limited, a subsidiary of the Company, has incorporated a wholly owned subsidiary in the name of “Heal plus Medical Services Private Limited” having CIN: U47721DC2026PTC471594, on May 20, 2026. The new subsidiary has not commenced business operations as of June 30, 2026, and hence has no financial impact on the consolidated results. 7. Aggarwal Hospital and Research Services Private Limited, a wholly owned subsidiary of the Company, has divested its entire 55% shareholding in Devina Derma Private Limited, a subsidiary of Aggarwal Hospital and Research Services Private Limited, for a consideration of INR 0.60 million. The transaction was completed on 05th June 2026 and since then Devina Derma Private Limited ceased to be a subsidiary of Aggarwal Hospital and Research Services Private Limited, and consequently, of the Company. This divestment has been undertaken by the company as a strategic management decision. 8. The Group's business activity primarily falls within a single reportable business segment namely Healthcare Service and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind AS 108- Segment Reporting. The Group does not distinguish revenues, costs and expenses between segments in its internal reporting, and report costs and expenses by nature as a whole. The Board of Directors (Chief Operating Decision Maker (CODM)) reviews the Consolidated Financial information when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group operates and manages its business as a single segment mainly through the sale of healthcare services. The Group operates in one geographic segment namely within India and hence no separate information for geographic segment wise disclosure is required. 9. The utilisation of the IPO proceeds is summarised below: Object of the issue as Utilisation planned Utilised up to Amount pending for utilisation per prospectus: as per prospectus June 30, 2026 as on June 30, 2026 Repayment/ prepayment, in full 3,800.00 3,800.00 - or in part, of outstanding borrowings availed by our Company and our Subsidiaries Funding capital expenditure for 605.00 195.19 409.81 development of new hospital by our Subsidiary Park Medicity (NCR) Private Limited Funding capital expenditure for 274.59 36.08 238.51 purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens Healthcare Private Limited and Ratnagiri Innovations Private Limited Unidentified inorganic acquisitions 2,453.18 2,453.18 - and general corporate purposes Total 7,132.77 6,484.45 648.32 Issue expenses towards IPO 567.23 567.23 - Grand Total 7,700.00 7,051.68 648.32 There is no deviation in the utilization of proceeds from the objects stated in the offer document and there is no variation in the terms of contract referred to in the prospectus. 10. During the quarter ended June 30, 2026 the Company did not receive any investor complaint. No complaints were pending resolution as on June 30, 2026. The Company has adequate systems and processes in place to address investor grievances in a timely manner in compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. 11. Previous period figures have been regrouped / reclassified wherever necessary to conform to current period classification and rounding off errors have been ignored. 12. The unaudited Consolidated financial results for the quarter ended June 30, 2026 are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement of employee defined benefit plans | (77.60) | (77.60) |
| Total Amount of items that will not be reclassified to profit and loss | (77.60) | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (19.50) | (19.50) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (58.10) | (58.10) |
| Whether results are audited or unaudited | Unaudited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Agiwal and Associates | Yes | 28-02-2029 | ||
|---|---|---|---|---|---|